3-HO-PCE: Difference between revisions

Line 3:

'''3-Hydroxyeticyclidine''' (commonly known as '''3-HO-PCE''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class. It produces potent, dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. Unlike its close structural analog [[3-HO-PCP]], this compound ~~is entirely novel and~~ has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.<ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref>

'''3-Hydroxyeticyclidine''' (commonly known as '''3-HO-PCE''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class. It produces potent, dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. Unlike its close structural analog [[3-HO-PCP]], this compound has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.<ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref>

Early discussions of this compound have revolved around whether it possesses an appreciable affinity for the [[μ-opioid]] [[receptor]] given its structural relationship to [[3-HO-PCP]], which has been shown to display affinity for the [[μ-opioid]] [[receptor]] in animal models.<ref name="3HOPCEsar">Kalir, A., S. Maayani, M. Rehavi, R. Elkavetz, I. Pri-Bar, O. Buchman and M. Sokolovsky, 1978, Structure activity relationship of some phencyclidine derivatives; in vivo studies in mice, European J. Med. Chem. 13, 17.</ref> Whether it produces any of its theorized [[opioid]] effects in humans is the subject of ongoing discussion. If it does, 3-HO-PCE may pose unique risks relative to other dissociatives, particularly when it is redosed.

Line 9:

Following other substances of its class, particularly [[methoxetamine]] (MXE), [[phencyclidine]] (PCP), and [[3-MeO-PCE]], it is speculated to to be able to induce a state known as "[[dissociatives#Subjective effects|dissociative anesthesia]]". Early reports suggest that this state is difficult to reach relative to other [[dissociatives]], and its general effects profile has been characterized as "lying halfway between [[3-MeO-PCP]] and [[3-MeO-PCE]]."

~~It should be noted that no independent lab analysis has been conducted for any of~~ the ~~batches that~~ have been ~~marketed~~ to date.~~{{citation needed}} All current information regarding this compound should be regarded with extreme caution~~.

Research surrounding 3-HO-PCE sold on the grey market is almost entirely speculative. As phencyclidines such as [[PCP]] have been found unlikely to produce metabolites such as [[3-HO-PCP]] to date, it is it unlikely that [[3-HO-PCE]] would be a natural metabolite from the use of [[PCE]] in the human body. <refname="https://academic.oup.com/jat/article-abstract/10/3/107/722949?redirectedFrom=fulltext" />

~~There~~ is a ~~complete~~ lack of data on the pharmacological properties~~, metabolism,~~ and toxicity of 3-HO-PCE, ~~and it has an extremely~~ brief history of human usage. ~~It is exclusively~~ distributed ~~as a gray area [[research chemical]] by online vendors~~.<ref name="PCP2MXE /> Due to ~~its potential~~ habit-forming properties~~, and unknown toxicity profile~~, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.

As with many similar eticyclidines, there is a lack of data on the pharmacological properties and toxicity of 3-HO-PCE, because of its brief history of human usage. There have been no analytical studies conducted on samples of 3-HO-PCE distributed through the grey market via independent laboratories.<ref name="PCP2MXE /> Due to an unknown toxicity profile and likely similar habit-forming properties shared by other hydroxylanated arylcyclohexylamines, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.

==History and culture==

@@ Line 3: / Line 3: @@
 {{SubstanceBox/3-HO-PCE}}
-'''3-Hydroxyeticyclidine''' (commonly known as '''3-HO-PCE''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class. It produces potent, dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. Unlike its close structural analog [[3-HO-PCP]], this compound is entirely novel and has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.<ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref>
+'''3-Hydroxyeticyclidine''' (commonly known as '''3-HO-PCE''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class. It produces potent, dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. Unlike its close structural analog [[3-HO-PCP]], this compound has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.<ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref>
 Early discussions of this compound have revolved around whether it possesses an appreciable affinity for the [[μ-opioid]] [[receptor]] given its structural relationship to [[3-HO-PCP]], which has been shown to display affinity for the  [[μ-opioid]] [[receptor]] in animal models.<ref name="3HOPCEsar">Kalir, A., S. Maayani, M. Rehavi, R. Elkavetz, I. Pri-Bar, O. Buchman and M. Sokolovsky, 1978, Structure activity relationship of some phencyclidine derivatives; in vivo studies in mice, European J. Med. Chem. 13, 17.</ref> Whether it produces any of its theorized [[opioid]] effects in humans is the subject of ongoing discussion. If it does, 3-HO-PCE may pose unique risks relative to other dissociatives, particularly when it is redosed.
@@ Line 9: / Line 9: @@
 Following other substances of its class, particularly [[methoxetamine]] (MXE), [[phencyclidine]] (PCP), and [[3-MeO-PCE]], it is speculated to to be able to induce a state known as "[[dissociatives#Subjective effects|dissociative anesthesia]]". Early reports suggest that this state is difficult to reach relative to other [[dissociatives]], and its general effects profile has been characterized as "lying halfway between [[3-MeO-PCP]] and [[3-MeO-PCE]]."
-It should be noted that no independent lab analysis has been conducted for any of the batches that have been marketed to date.{{citation needed}} All current information regarding this compound should be regarded with extreme caution.
+Research surrounding 3-HO-PCE sold on the grey market is almost entirely speculative. As phencyclidines such as [[PCP]] have been found unlikely to produce metabolites such as [[3-HO-PCP]] to date, it is it unlikely that [[3-HO-PCE]] would be a natural metabolite from the use of [[PCE]] in the human body. <refname="https://academic.oup.com/jat/article-abstract/10/3/107/722949?redirectedFrom=fulltext" />
-There is a complete lack of data on the pharmacological properties, metabolism, and toxicity of 3-HO-PCE, and it has an extremely brief history of human usage. It is exclusively distributed as a gray area [[research chemical]] by online vendors.<ref name="PCP2MXE /> Due to its potential habit-forming properties, and unknown toxicity profile, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.
+As with many similar eticyclidines, there is a lack of data on the pharmacological properties and toxicity of 3-HO-PCE, because of its brief history of human usage. There have been no analytical studies conducted on samples of 3-HO-PCE distributed through the grey market via independent laboratories.<ref name="PCP2MXE /> Due to an unknown toxicity profile and likely similar habit-forming properties shared by other hydroxylanated arylcyclohexylamines, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.
 ==History and culture==